SYS-CON MEDIA Authors: Adine Deford, Cynthia Dunlop, Harry Trott, Xenia von Wedel, Peter Silva

News Feed Item

Skystar Bio-Pharmaceutical Reports First Quarter Fiscal Year 2014 Financial Results

Revenue of $6.8 Million; Net Income $1 Million; $0.13 Fully Diluted EPS; Conference Call to Be Held Friday, May 16, 2014 at 7:45 AM ET

XI'AN, CHINA -- (Marketwired) -- 05/15/14 -- Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company"), a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, today reported unaudited first quarter fiscal year 2014 earnings, for the period ended March 31, 2014.
First Quarter 2014 Summary

  • Revenue increase 23.5% YoY to $6.8 million as follows:
    • Veterinary medicines totaled $4.8 million, up 40.6% YoY
    • Pro-biotic micro-organism products totaled $1.5 million, decreasing 8.8% YoY
    • Feed additives totaled $0.3 million, increasing 15.5% YoY
    • Veterinary vaccines totaled $0.1 million, increasing 4.1% YoY
  • Gross Profit of $2.8 million increased 8.6% for the first three months of fiscal 2014 YoY
  • Gross Margin of 41.3% for the first three months of fiscal 2014, compared to 47% in the prior 2013 period
  • Net Income of $1 million or $0.13 per fully diluted share, as compared with $0.7 million or $0.09 fully diluted share YoY

Management's Comments
Mr. Weibing Lu, Chairman and Chief Executive Officer of Skystar, commented, "Skystar is pleased with unaudited first quarter results seeing increases in both year over year top and bottom line profitability. Skystar's revenue growth was driven by Veterinary medicine which grew 40% year over year with solid contributions coming from Skystar's other segments. The increased utilization rates for Skystar's veterinary medication production facility were realized following the receipt of more product permits from the Ministry of Agriculture. Skystar's YoY gross margin compression from 47% to 41% for the current reporting quarter was anticipated due to increased production coming from the lower margin veterinary medications line for which the Company recently received some product permits, and increased manufacturing overhead as we successfully completed our Huxian vaccine plant construction. We expect for manufacturing to continue to scale up throughout the year in preparation for the majority of Skystar's sales coming after the first quarter coinciding with China's celebration of the Lunar New Year holiday. Skystar expects a steady growth trajectory once all of its manufacturing plants can be completed and brought to full utilization rates," concluded Mr. Lu.

Financial Summary

For the year ended March 31, 2014, Skystar's revenues were roughly $6.8 million as compared to revenues of $5.5 million for the three months ended March 31, 2013, an increase of $1.3 million or 23.5%. Overall increase in revenue was due to increase in manufacturing at the Company's Huxian plant in combination with receiving product permits by the Ministry of Agriculture to manufacture select veterinary medications.

A breakdown of the year's revenue by production line is as follows:

- Revenue from sales of our veterinary medications increased by $1.4 million or 40.6%, from $3.4 million for the three months ended March 31, 2013 to $4.8 million for the three months ended March 31, 2014.

- Revenue from probiotic products decreased by $146,000 roughly or 8.8% from $1.7 million for the three months ended March 31, 2013 to $1.5 million for the three months ended March 31, 2014. The decrease was due to weak market demand for probiotics due to a decline in pork prices in the first quarter, which discouraged farmers from increasing their livestock farming.

- Revenue from feed additives increased by $44,000 or 15.5% from $286,000 for the three months ended March 31, 2013 to $330,000 for the three months ended March 31, 2014.

- Vaccine revenues increased by $5,000 or 4.1% from $131,000 for the three months ended March 31, 2013 to $136,000 for the three months ended March 31, 2014. Vaccine production is expected to commence production at Skystar's new facility during the second half of 2014.

Gross profit for the quarter was up $223,000 or 8.6% from $2.6 million for the three months ended March31, 2013 to $2.8 million for the three months ended March 31, 2014. Gross margin was 41.3%, down from 47% in the same year ago period. The decreased gross margin was mainly because the majority of our revenue during the year came from less profitable veterinary medications product lines.

Operating expenses for the quarter increased 8% to $1.6 million or 24% of total revenue, compared with $1.5 million for the same year ago period.

Research and development costs were insignificant for both the first quarter of 2014 and 2013 as there was no significant R&D effort undertaken during the first quarter because of the Chinese New Year. Research and development costs are expected to increase as new projects begin throughout the remainder of fiscal 2014.

Selling expenses totaled $370,000 for the three months ended March 31, 2014 as compared to $317,000 for the three months ended March 31, 2013, an increase of 16.5%.

General and administrative expenses totaled $1.3 million for the three months ended March 31, 2014 as compared to $1.2 million for the three months ended March 31, 2013, an increase 5.4%.

Operating income for March 31, 2014 was $1.2 million up $100,000 or 9.5% from the prior year. Operating margin was 17% versus 19% in the year ago period.

Net income for the quarter was $975,000 million or $0.13 per fully diluted share. This compares to net income of $713,000 or $0.09 per fully diluted share for the year ago period.

As of March 31, 2014, Skystar had approximately $6.9 million in cash, current assets of $88.4 million and total current liabilities of $23.7 million which resulted in net working capital of $64.7 million.

Mr. Lu concluded, "Skystar has reported a strong start to the fiscal 2014 reporting cycle. The Company believes that it has built a strong framework as the only U.S. listed animal pharmaceutical play in China. The completed and newly GMP certified manufacturing facility in Huxian gives Skystar the ability to produce veterinary medicines and vaccines utilizing modern batch processes, increasing production efficiencies and volume of product produced. More importantly, the Company has been able to launch and expand infrastructure within the tougher regulatory framework of China's new requirements for GMP production facilities. These modern manufacturing standards and rules help to ensure the safety of China's food supply as agriculture and animal husbandry standards in China move towards modern standards and industrialization," concluded Mr. Lu.

Business Outlook
Skystar currently maintains business outlook and anticipates delivering an 8% to 18% year over year increase in top line revenue for fiscal 2014 as compared to the prior year. The expected revenue range is $46 million to $50 million with gross margin of roughly 50% for fiscal 2014.

Conference Call Information
The Company will host a conference call on Friday, May 16, 2014 to discuss its financial results for the year ended March 31, 2014. Skystar's conference call will begin promptly at 7:45 a.m. EST to review first quarter fiscal 2014 financial and operational performance. Mr. Weibing Lu, Skystar's chairman and chief executive officer, will host the call, which will be webcast live.

Webcast will be made available on the investor relations section of the Skystar corporate website at http://www.investorcalendar.com/IC/CEPage.asp?ID=172772.

Phone dial-in to the conference call will be available in North America by dialing +1 (877) 407-8031 or internationally by dialing +1 (201) 689-8031.

An audio replay of the conference call will be available approximately two hours following the conclusion of the call and for the following 30 day period. To access the replay in North America, dial +1 (877) 660-6853 or, when calling internationally, dial +1 (201) 612-7415, referencing conference ID # 13582730.

To be added to the Company's email distribution for future news releases, please send your request to [email protected].

About Skystar Bio-Pharmaceutical Company

Skystar is a China-based developer, manufacturer and distributor of veterinary healthcare and medical care products. Skystar has four product lines: veterinary medicines, probiotics, vaccines and feed additives formulated and packaged in house across several modern manufacturing and distributions facilities. Skystar's distribution network includes almost 3,000 distribution agents of which 360 are franchised stores with exclusivity agreements covering 29 provinces throughout China. For additional information, please visit http://www.skystarbio-pharmaceutical.com.

Financial Statements


            SKYSTAR BIO-PHARMACEUTICAL COMPANY AND SUBSIDIARIES
         CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
             FOR THE THREE MONTHS ENDED MARCH 31, 2014 AND 2013
                                (Unaudited)

                                                     Three Months Ended
                                                         March 31,
                                                ---------------------------
                                                    2014           2013
                                                ------------   ------------

REVENUE, net                                   $   6,832,588  $   5,530,741

COST OF REVENUE                                    4,009,403      2,930,886
                                                ------------   ------------

GROSS PROFIT                                       2,823,185      2,599,855
                                                ------------   ------------

OPERATING EXPENSES:
  Research and development costs                       4,213            461
  Selling expenses                                   370,208        317,836
  General and administrative expenses              1,276,417      1,211,273
                                                ------------   ------------
    Total operating expenses                       1,650,838      1,529,570
                                                ------------   ------------

INCOME FROM OPERATIONS                             1,172,347      1,070,285
                                                ------------   ------------

OTHER INCOME (EXPENSE):
  Other income (expense), net                        154,919           (187)
  Interest income                                    170,665        148,845
  Interest expense                                   (75,934)      (189,392)
  Change in fair value of purchase option
   liability                                         (16,520)         4,466
                                                ------------   ------------
    Total other income (expense), net                233,130        (36,268)
                                                ------------   ------------

INCOME BEFORE PROVISION FOR INCOME TAXES           1,405,477      1,034,017

PROVISION FOR INCOME TAXES                           430,027        321,284
                                                ------------   ------------

NET INCOME                                           975,450        712,733

OTHER COMPREHENSIVE INCOME :
  Foreign currency translation adjustment           (966,949)       550,883
                                                ------------   ------------

COMPREHENSIVE INCOME                           $       8,501  $   1,263,616
                                                ============   ============

EARNINGS PER SHARE:
  Basic                                        $        0.13  $        0.09
                                                ============   ============
  Diluted                                      $        0.13  $        0.09
                                                ============   ============

WEIGHTED AVERAGE NUMBER OF COMMON SHARES:
  Basic                                            7,676,268      7,613,712
                                                ============   ============
  Diluted                                          7,700,734      7,613,712
                                                ============   ============



             SKYSTAR BIO-PHARMACEUTICAL COMPANY AND SUBSIDIARIES
                    CONDENSED CONSOLIDATED BALANCE SHEETS

                                   ASSETS
                                                    March 31,   December 31,
                                                      2014          2013
                                                   (Unaudited)
                                                  ------------  ------------

CURRENT ASSETS:
  Cash                                           $   6,848,905 $   8,142,296
  Accounts receivable, net of allowance for
   doubtful accounts of $960,578 (Unaudited) and
   $602,243 as of March 31, 2014 and December
   31, 2013, respectively                           12,663,549    11,009,498
  Inventories                                       25,265,783    25,903,586
  Deposits, prepaid expenses and other
   receivables                                       1,608,405     2,134,163
  Prepayments to suppliers                          40,541,475    41,061,144
  Loans receivable                                   1,046,835             -
  Deferred tax assets                                  403,372       364,425
                                                  ------------  ------------
    Total current assets                            88,378,324    88,615,112
                                                  ------------  ------------

PROPERTY, PLANT AND EQUIPMENT, NET                  30,417,653    28,269,155

CONSTRUCTION-IN-PROGRESS                             6,470,772     9,284,947

OTHER ASSETS:
  Long-term prepayments                              4,592,751     4,633,614
  Long-term prepayments for acquisitions                     -       183,344
  Intangible assets, net                             5,130,454     5,237,255
                                                  ------------  ------------
    Total other assets                               9,723,205    10,054,213
                                                  ------------  ------------
      Total assets                               $ 134,989,954 $ 136,223,427
                                                  ============  ============

                    LIABILITIES AND SHAREHOLDERS' EQUITY

CURRENT LIABILITIES:
  Accounts payable                               $   4,615,614 $   3,303,531
  Other payables and accrued expenses                6,551,419     6,467,605
  Short-term loans                                   5,680,500    10,640,500
  Deposits from customers                            1,991,907     1,877,211
  Taxes payable                                      2,852,844     1,315,486
  Due to related parties                             1,962,238     1,361,548
                                                  ------------  ------------
    Total current liabilities                       23,654,522    24,965,881
                                                  ------------  ------------

OTHER LIABILITIES:
  Deferred government grant                            795,270       802,130
  Purchase option liability                             78,960        62,440
                                                  ------------  ------------
    Total other liabilities                            874,230       864,570
                                                  ------------  ------------
      Total liabilities                             24,528,752    25,830,451
                                                  ------------  ------------

COMMITMENTS AND CONTINGENCIES

SHAREHOLDERS' EQUITY
  Preferred stock, $0.001 par value, 50,000,000
   shares authorized, No Series "A" shares
   authorized, 48,000,000 Series B shares
   authorized. No Series "B" shares issued and
   outstanding                                               -             -
  Common stock, $0.001 par value, 40,000,000
   shares authorized, 7,604,800 shares issued
   and outstanding as of March 31,2014
   (Unaudited) and December 31, 2013                     7,605         7,605
  Paid-in capital                                   37,690,867    37,631,142
  Statutory reserves                                 5,952,692     5,952,692
  Retained earnings                                 55,965,604    54,990,154
  Accumulated other comprehensive income            10,844,434    11,811,383
                                                  ------------  ------------
      Total shareholders' equity                   110,461,202   110,392,976
                                                  ------------  ------------
        Total liabilities and shareholders'
         equity                                  $ 134,989,954 $ 136,223,427
                                                  ============  ============



            SKYSTAR BIO-PHARMACEUTICAL COMPANY AND SUBSIDIARIES
              CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
             FOR THE THREE MONTHS ENDED MARCH 31,2014 AND 2013
                                (Unaudited)

                                                     Three Months Ended
                                                         March 31,
                                                ---------------------------
                                                    2014           2013
                                                ------------   ------------
CASH FLOWS FROM OPERATING ACTIVITIES:
  Net income                                   $     975,450  $     712,733
  Adjustments to reconcile net income to net
   cash (used in) provided by operating
   activities:
      Depreciation                                   400,291        313,561
      Amortization                                    62,477         60,872
      Provision for doubtful accounts                366,218        351,534
      Share based compensation                        59,725          4,340
      Change in fair value of purchase option
       liability                                      16,520         (4,466)
      Deferred tax assets                            (42,380)             -
    Change in operating assets and liabilities
      Accounts receivable                         (2,127,566)    (1,725,889)
      Inventories                                    419,398       (557,269)
      Deposits, prepaid expenses and other
       receivables                                   513,005        292,476
      Prepayments to suppliers                       169,771     (9,696,136)
      Accounts payable                             1,350,410      1,023,288
      Other payables and accrued expenses            135,167       (339,030)
      Deferred government grants                           -       (159,320)
      Deposits from customers                        131,733         28,061
      Taxes payable                                1,560,250       (288,655)
      Due to related parties                         606,813        201,325
                                                ------------   ------------
        Net cash provided by (used in)
         operating activities                      4,597,282     (9,782,575)
                                                ------------   ------------

CASH FLOWS FROM INVESTING ACTIVITIES:
  Refund of long-term prepayments                    184,387              -
  Loans to third parties                          (1,054,704)             -
  Payments on construction-in-progress               (53,195)             -
                                                ------------   ------------
Net cash used in investing activities               (923,512)             -
                                                ------------   ------------

CASH FLOWS FROM FINANCING ACTIVITIES:
  Proceeds from short-term loans                           -      4,779,600
  Repayment of short-term loans                   (4,905,600)    (2,389,800)
                                                ------------   ------------
  Net cash (used in) provided by financing
   activities                                     (4,905,600)     2,389,800
                                                ------------   ------------

EFFECT OF EXCHANGE RATE CHANGES ON CASH              (61,561)        50,421
                                                ------------   ------------

DECREASE IN CASH                                  (1,293,391)    (7,342,354)

CASH, beginning of period                          8,142,296     11,321,848
                                                ------------   ------------

CASH, end of period                            $   6,848,905  $   3,979,494
                                                ============   ============

SUPPLEMENTAL DISCLOSURE OF CASH FLOW
 INFORMATION:
  Cash paid for income tax                     $           -  $           -
                                                ============   ============
  Cash paid for interest                       $     129,129  $     181,426
                                                ============   ============
  Non-cash investing activities
  Construction-in-progress transferred to
   property, plant and equipment               $   2,787,566  $           -
                                                ============   ============



             SKYSTAR BIO-PHARMACEUTICAL COMPANY AND SUBSIDIARIES
          CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
                  FOR THE THREE MONTHS ENDED MARCH 31,2014
                                 (Unaudited)



                          Common stock
                       ------------------    Paid-in
                         Shares    Amount    capital
                       ----------  ------  ----------
BALANCE,January 1,
 2014                   7,604,800 $ 7,605 $37,631,142

Foreign currency
 translation                    -       -           -
Share-based
 compensation                   -       -      59,725
Net income                      -       -           -
                       ----------  ------  ----------

BALANCE, March 31,
 2014                   7,604,800 $ 7,605 $37,690,867
                       ==========  ======  ==========


                            Retained earnings     Accumulated
                        ------------------------     other
                         Statutory                comprehensive
                         reserves   Unrestricted     income        Total
                        ----------  ------------  -----------   -----------
BALANCE,January 1,
 2014                  $ 5,952,692 $  54,990,154 $ 11,811,383  $110,392,976

Foreign currency
 translation                     -             -     (966,949)     (966,949)
Share-based
 compensation                    -             -            -        59,725
Net income                               975,450            -       975,450
                        ----------  ------------  -----------   -----------

BALANCE, March 31,
 2014                  $ 5,952,692 $  55,965,604 $ 10,844,434  $110,461,202
                        ==========  ============  ===========   ===========

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and include, without limitation, the Company's financial projections, and revenue guidance, expectations relating to scaling up of the production and the plant production capabilities, statements relating to the timing of various regulatory certifications, or information regarding the progress of new product development. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results.

Contacts:

Skystar Bio-Pharmaceutical Company
Scott Cramer
Director - Corporate Development & U.S. Representative
(407) 645-4433

Grayling
Investor Relations
Christopher Chu
(908) 251-9869
Email Contact

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
The 3rd International Internet of @ThingsExpo, co-located with the 16th International Cloud Expo - to be held June 9-11, 2015, at the Javits Center in New York City, NY - announces that its Call for Papers is now open. The Internet of Things (IoT) is the biggest idea since the creation of the Worldwide Web more than 20 years ago.
"We help companies that are using a lot of Software as a Service. We help companies manage and gain visibility into what people are using inside the company and decide to secure them or use standards to lock down or to embrace the adoption of SaaS inside the company," explained Scott Kriz, Co-founder and CEO of Bitium, in this SYS-CON.tv interview at 15th Cloud Expo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
15th Cloud Expo, which took place Nov. 4-6, 2014, at the Santa Clara Convention Center in Santa Clara, CA, expanded the conference content of @ThingsExpo, Big Data Expo, and DevOps Summit to include two developer events. IBM held a Bluemix Developer Playground on November 5 and ElasticBox held a Hackathon on November 6. Both events took place on the expo floor. The Bluemix Developer Playground, for developers of all levels, highlighted the ease of use of Bluemix, its services and functionalit...
The 4th International DevOps Summit, co-located with16th International Cloud Expo – being held June 9-11, 2015, at the Javits Center in New York City, NY – announces that its Call for Papers is now open. Born out of proven success in agile development, cloud computing, and process automation, DevOps is a macro trend you cannot afford to miss. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the world's large...
Some developers believe that monitoring is a function of the operations team. Some operations teams firmly believe that monitoring the systems they maintain is sufficient to run the business successfully. Most of them are wrong. The complexity of today's applications have gone far and beyond the capabilities of "traditional" system-level monitoring tools and approaches and requires much broader knowledge of business and applications as a whole. The goal of DevOps is to connect all aspects of app...
SAP is delivering break-through innovation combined with fantastic user experience powered by the market-leading in-memory technology, SAP HANA. In his General Session at 15th Cloud Expo, Thorsten Leiduck, VP ISVs & Digital Commerce, SAP, discussed how SAP and partners provide cloud and hybrid cloud solutions as well as real-time Big Data offerings that help companies of all sizes and industries run better. SAP launched an application challenge to award the most innovative SAP HANA and SAP HANA...
When an enterprise builds a hybrid IaaS cloud connecting its data center to one or more public clouds, security is often a major topic along with the other challenges involved. Security is closely intertwined with the networking choices made for the hybrid cloud. Traditional networking approaches for building a hybrid cloud try to kludge together the enterprise infrastructure with the public cloud. Consequently this approach requires risky, deep "surgery" including changes to firewalls, subnets...
Want to enable self-service provisioning of application environments in minutes that mirror production? Can you automatically provide rich data with code-level detail back to the developers when issues occur in production? In his session at DevOps Summit, David Tesar, Microsoft Technical Evangelist on Microsoft Azure and DevOps, will discuss how to accomplish this and more utilizing technologies such as Microsoft Azure, Visual Studio online, and Application Insights in this demo-heavy session.
DevOps is all about agility. However, you don't want to be on a high-speed bus to nowhere. The right DevOps approach controls velocity with a tight feedback loop that not only consists of operational data but also incorporates business context. With a business context in the decision making, the right business priorities are incorporated, which results in a higher value creation. In his session at DevOps Summit, Todd Rader, Solutions Architect at AppDynamics, discussed key monitoring techniques...
Cultural, regulatory, environmental, political and economic (CREPE) conditions over the past decade are creating cross-industry solution spaces that require processes and technologies from both the Internet of Things (IoT), and Data Management and Analytics (DMA). These solution spaces are evolving into Sensor Analytics Ecosystems (SAE) that represent significant new opportunities for organizations of all types. Public Utilities throughout the world, providing electricity, natural gas and water,...
The security devil is always in the details of the attack: the ones you've endured, the ones you prepare yourself to fend off, and the ones that, you fear, will catch you completely unaware and defenseless. The Internet of Things (IoT) is nothing if not an endless proliferation of details. It's the vision of a world in which continuous Internet connectivity and addressability is embedded into a growing range of human artifacts, into the natural world, and even into our smartphones, appliances, a...
How do APIs and IoT relate? The answer is not as simple as merely adding an API on top of a dumb device, but rather about understanding the architectural patterns for implementing an IoT fabric. There are typically two or three trends: Exposing the device to a management framework Exposing that management framework to a business centric logic Exposing that business layer and data to end users. This last trend is the IoT stack, which involves a new shift in the separation of what stuff happe...
The Internet of Things is tied together with a thin strand that is known as time. Coincidentally, at the core of nearly all data analytics is a timestamp. When working with time series data there are a few core principles that everyone should consider, especially across datasets where time is the common boundary. In his session at Internet of @ThingsExpo, Jim Scott, Director of Enterprise Strategy & Architecture at MapR Technologies, discussed single-value, geo-spatial, and log time series dat...
An entirely new security model is needed for the Internet of Things, or is it? Can we save some old and tested controls for this new and different environment? In his session at @ThingsExpo, New York's at the Javits Center, Davi Ottenheimer, EMC Senior Director of Trust, reviewed hands-on lessons with IoT devices and reveal a new risk balance you might not expect. Davi Ottenheimer, EMC Senior Director of Trust, has more than nineteen years' experience managing global security operations and asse...
The Internet of Things will greatly expand the opportunities for data collection and new business models driven off of that data. In her session at @ThingsExpo, Esmeralda Swartz, CMO of MetraTech, discussed how for this to be effective you not only need to have infrastructure and operational models capable of utilizing this new phenomenon, but increasingly service providers will need to convince a skeptical public to participate. Get ready to show them the money!